Restricted occupancy models for neutralization of HIV virions and populations

Journal of Theoretical Biology

Volumn 283, Issue 1, 2011, Pages 192-202

  Magnus, Carsten ^a   Regoes, Roland R ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Antibodies; HIV neutralization; Restricted occupancy theory; Stoichiometry of neutralization

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS; INFECTIOUS DISEASE; NEUTRALIZATION; NUMERICAL MODEL; STOICHIOMETRY; THEORETICAL STUDY;

ARTICLE; CELL TRANSPORT; HUMAN IMMUNODEFICIENCY VIRUS; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; POPULATION SIZE; PRIORITY JOURNAL; RESTRICTED OCCUPANCY THEORY; STOICHIOMETRY; THEORY; VIRION; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; ANTIGEN-ANTIBODY REACTIONS; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; MODELS, IMMUNOLOGICAL; VIRION; VIRUS INTERNALIZATION;

EID: 79958843060     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2011.06.004     Document Type: Article

References (39)

1. Burton D. Antibodies, viruses and vaccines. Nature Reviews Immunology 2002, 2(9):706-713.
2. Burton D., Pyati J., Koduri R., Sharp S., Thornton G., Parren P., Sawyer L., Hendry R., Dunlop N., Nara P., Lamacchia M., Garratty E., Stiehm E., Bryson Y., Cao Y., Moore J., Ho D., Barbas C. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266(5187):1024-1027.
3. Burton D.R., Barbas C.F., Persson M.A., Koenig S., Chanock R.M., Lerner R.A. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proceedings of the National Academy of Sciences USA 1991, 88(22):10134-10137.
4. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nature Immunology 2004, 5(3):233-236.
5. Charalambides C. On a restricted occupancy model and its applications. Biometrical Journal 1981, 23(6):601-610.
6. Charalambides C. On restricted and pseudo-contagious occupancy distributions. Journal of Applied Probability 1983, 20(4):872-876.
7. Della-Porta A.J., Westaway E.G. A multi-hit model for the neutralization of animal viruses. Journal of General Virology 1977, 38:1-19.
8. Dimmock N. Mechanisms of neutralization of animal viruses. Journal of General Virology 1984, 65(June):1015-1022.
9. Earp L., Delos S., Park H., White J. The many mechanisms of viral membrane fusion proteins. Current Topics in Microbiology and Immunology 2004, 285:25-66.
10. Fang K. A restricted occupancy problem. Journal of Applied Probability 1982, 19(3):707-711.
11. Freed E., Myers D., Risser R. Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp4l. Proceedings of the National Academy of Sciences USA 1990, 87(12):4650-4654.
12. Freund J., Pozner A. Some results on restricted occupancy theory. Annals of Mathematical Statistics 1956, 27(2):537-540.
13. Hedestam G.B.K., Fouchier R.A.M., Phogat S., Burton D.R., Sodroski J., Wyatt R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nature Reviews Microbiology 2008, 6(2):143-155. URL http://dx.doi.org/10.1038/nrmicro1819.
14. Ho D., McKeating J., Xi L., Moudgil T., Daar E., Sun N., Robinson J. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. Journal of Virology 1991, 65(1):489-493.
15. Johnson N., Kotz S. Urn Models and Their Application-An Approach to Modern Discrete Probability Theory 1977, John Wiley and Sons.
16. Klasse P.J. Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody. Virology 2007, 369(2):245-262.
17. Klasse P.J., Sattentau Q.J. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. Journal of General Virology 2002, 83(Pt 9):2091-2108.
18. Klatzmann D., Champagne E., Chamaret S., Gruest J., Guetard D., Hercend T., Gluckmann J., Montagnier L. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312(5996):767-768.
19. Kwong P., Wyatt R., Robinson J., Sweet R., Sodroski J., Hendrickson W. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393(6686):648-659.
20. Li M., Gao F., Mascola J., Stamatatos L., Polonis V., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K., Bilska M., Kothe D., Salazar-Gonzalez J., Wei X., Decker J., Hahn B., Montefiori D. Human immunodeficiency virus type 1 env clones from acute and early subtype b infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of Virology 2005, 79(16):10108-10125.
21. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., Decker J.M., Li Y., Salazar M.G., Polonis V.R., Mlisana K., Karim S.A., Hong K., Greene K.M., Bilska M., Zhou J., Allen S., Chomba E., Mulenga J., Vwalika C., Gao F., Zhang M., Korber B.T.M., Hunter E., Hahn B.H., Montefiori D.C. Genetic and neutralization properties of subtype c human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. Journal of Virology 2006, 80(23):11776-11790.
22. Magnus C., Regoes R.R. Estimating the stoichiometry of HIV neutralization. PLoS Computational Biology 2010, 6(3):e1000713.
23. Magnus C., Rusert P., Bonhoeffer S., Trkola A., Regoes R.R. Estimating the stoichiometry of human immunodeficiency virus entry. Journal of Virology 2009, 83(3):1523-1531.
24. Moore J., Ho D. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human-immunodeficiency-virus type-1 are highly prevalent in sera of infected humans. Journal of Virology 1993, 67(2):863-875.
25. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Rüker F., Katinger H. A conserved neutralizing epitope on gp41 of human-immunodeficiency-virus type-1. Journal of Virology 1993, 67(11):6642-6647.
26. Posner M., Hideshima T., Cannon T., Mukherjee M., Mayer K., Byrn R. An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection. Journal of Immunology 1991, 146(12):4325-4332.
27. R Development Core Team, 2009. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, ISBN 3-900051-07-0. http://www.R-project.org.
28. Robey W., Safai B., Oroszlan S., Arthur L., Gonda M., Gallo R., Fischinger P. Characterization of envelope and core structural gene-products of HTLV-III with sera from AIDS patients. Science 1985, 228(4699):593-595.
29. Sattentau Q., Moore J. Conformational-changes induced in the human-immunodeficiency-virus envelope glycoprotein by soluble cd4 binding. Journal of Experimental Medicine 1991, 174(2):407-415.
30. Schonning K., Lund O., Lund O.S., Hansen J.-E.S. Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1. Journal of Virology 1999, 8364-8370.
31. Thali M., Moore J., Furman C., Charles M., Ho D., Robinson J., Sodroski J. Characterization of conserved human-immunodeficiency-virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. Journal of Virology 1993, 67(7):3978-3988.
32. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. Journal of Virology 1996, 70(2):1100-1108.
33. Veronese F., Devico A., Copeland T., Oroszlan S., Gallo R., Sarngadharan M. Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 1985, 229(4720):1402-1405.
34. Walker L., Phogat S., Chan-Hui P., Wagner D., Phung P., Goss J., Wrin T., Simek M., Fling S., Mitcham J., Lehrman J., Priddy F., Olsen O., Frey S., Hammond P., Kaminsky S., Zamb T., Moyle M., Koff W., Poignard P., Burton D. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(5950):285-289.
35. West A.P., Galimidi R.P., Foglesong C.P., Gnanapragasam P., Klein J., Bjorkman P. Evaluation of CD4-CD4i antibody architectures yields potent, broadly cross-reactive anti-human immunodeficiency virus reagents. Journal of Virology 2010, 84(1):261-269.
36. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280(5371):1884-1888.
37. Yang X., Kurteva S., Lee S., Sodroski J. Stoichiometry of antibody neutralization of human immunodeficiency virus type 1. Journal of Virology 2005, 79(6):3500-3508.
38. Yang X., Kurteva S., Ren X., Lee S., Sodroski J. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. Journal of Virology 2005, 79(19):12132-12147.
39. Zhu P., Liu J., Bess J., Chertova E., Lifson J.D., Grise H., Ofek G.A., Taylor K.A., Roux K.H. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441(7095):847-852.